PledPharma AB’s Phase IIb studies to reduce chemotherapy-induced side effects in colorectal cancer have given the Swedish biotech what it needs to initiate discussions with regulators to plan Phase III trials, and also credibility to approach would-be commercial partners.
Headline results from the Phase IIb study of PledOx (calmangafodipir) showed a clinically relevant reduction in the incidence of sensory...